Sorafenib in patients with refractory or recurrent multiple myeloma

Hematological Oncology

Volumn 31, Issue 4, 2013, Pages 197-200

  Yordanova, Anna ^a   Hose, Dirk ^b   Neben, Kai ^b   Witzens Harig, Mathias ^b   Gütgemann, Ines ^a   Raab, Marc Steffen ^b   Moehler, Thomas ^b   Goldschmidt, Hartmut ^b   Schmidt Wolf, Ingo Gh ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Multiple myeloma; Phase II clinical trial; Recurrent; Refractory; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; B RAF KINASE; C REACTIVE PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; RAS PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

MULTIPLE MYELOMA; PHASE II CLINICAL TRIAL; RECURRENT; REFRACTORY; SORAFENIB;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG ERUPTIONS; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NIACINAMIDE; PAIN; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84889093852     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2043     Document Type: Article

References (26)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546-1558.
3. Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009; 114: 128-143.
4. Hose D, Rème T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009; 113: 4331-4340.
5. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757.
6. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
7. Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 2009; 28: 3866-3879.
8. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
9. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Oncogene 2010; 29: 1190-1202.
10. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008; 22: 2280-2284.
11. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212-224.
12. Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235-239.
13. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica 2006; 91: 1033-1040.
14. Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190-1202.
15. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
16. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300-309.
17. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1988; 102: 1115-1123.
18. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
19. Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011; 22: 1812-1823.
20. National Cancer Institute. Common terminology criteria for adverse events v3.0 in edition. 2003. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
21. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.
22. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011; 78: 24-32.
23. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009; 28: 85-94.
24. Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010; 66: 837-844.
25. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11: 350-357.
26. Pölcher M, Eckhardt M, Coch C, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010; 66: 203-207.